Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses

Background Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients w...

Full description

Bibliographic Details
Main Authors:	Scott Zeller, Leslie Zun, James V. Cassella, Daniel A. Spyker, Paul P. Yeung
Format:	Article
Language:	English
Published:	Cambridge University Press 2017-11-01
Series:	BJPsych Open
Online Access:	https://www.cambridge.org/core/product/identifier/S2056472400002465/type/journal_article

Similar Items

Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change
by: Bruno Pacciardi, et al.
Published: (2019-02-01)

Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
by: Citrome L
Published: (2013-05-01)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
by: Faden J, et al.
Published: (2019-08-01)

Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder
by: L. San, et al.
Published: (2017-04-01)

<b>New drugs for the treatment of agitation in schizophrenia: a systematic review and meta-analysis of inhaled loxapine and infused sodium nitroprusside
by: Fernanda Stumpf Tonin, et al.
Published: (2017-05-01)

Loxapine in patient with clozapine-resistant psychosis
by: Jennifer Erley, PharmD, MBA, BCPS, et al.
Published: (2021-07-01)

Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
by: Scott L. Zeller, MD, et al.
Published: (2016-03-01)

Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia
by: Zhiwei Huang, et al.
Published: (2024-01-01)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
by: Jiang Huang, et al.
Published: (2021-08-01)

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
Published: (2005-05-01)

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
by: Fredrik Hieronymus, et al.
Published: (2021-08-01)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
by: Pál Czobor, et al.
Published: (2022-04-01)

Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review
by: Gabriele Nibbio, et al.
Published: (2022-08-01)

Loxapine to control agitation during weaning from mechanical ventilation
by: Stéphane Gaudry, et al.
Published: (2017-09-01)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
by: Koen Demyttenaere, et al.
Published: (2022-04-01)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials
by: Jagdeep T. Podichetty, et al.
Published: (2021-09-01)

Is the PANSS used correctly? a systematic review
by: Riedel Michael, et al.
Published: (2011-07-01)

Positive and Negative Syndrome Scale (PANSS) predictors of hospitalization during home treatment on 1045 patients with schizophrenia in acute crisis
by: R. Talisa, et al.
Published: (2023-03-01)

Loxapine-Induced Priapism: A Case Report and Review of the Literature on Antipsychotic-Induced Priapism
by: Alexandra L. Dodd, et al.
Published: (2021-01-01)

Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis
by: Citrome L, et al.
Published: (2024-03-01)

ECT versus Sham for clozapine-resistant schizophrenia: A secondary analysis of a pilot study based on PANSS-30 individual items
by: Débora Luciana Melzer-Ribeiro, et al.
Published: (2020-11-01)

Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room
by: San Luis, et al.
Published: (2011-03-01)

Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
by: Diane Merino, et al.
Published: (2022-06-01)

Loxapine in the Treatment of Manic and Psychotic Symptoms in an Individual Intolerant to Multiple Mood-Stabilizing and Antipsychotic Medications
by: David S. Im, et al.
Published: (2023-01-01)

Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses
by: Bortolato B, et al.
Published: (2015-12-01)

Neurobiology of schizophrenia and bipolar disorder
by: Mφller Hans-Jórgen
Published: (2008-04-01)

Pareidolia in Schizophrenia and Bipolar Disorder
by: Eid G. Abo Hamza, et al.
Published: (2021-12-01)

Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)?
by: Cecilie Marie Nielsen, et al.
Published: (2023-08-01)

Loxapine inhibits replication of hepatitis A virus in vitro and in vivo by targeting viral protein 2C.
by: Mami Matsuda, et al.
Published: (2024-03-01)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
by: P. Kølbæk, et al.
Published: (2021-04-01)

Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
by: Federica Pinna, et al.
Published: (2014-12-01)

Electroencephalographic Microstates in Schizophrenia and Bipolar Disorder
by: Fanglan Wang, et al.
Published: (2021-02-01)

Development and validation of an HPLC-UV method for analysis of methylphenidate hydrochloride and loxapine succinate in an activated carbon disposal system
by: Pooja Bakshi, et al.
Published: (2018-12-01)

Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version
by: Cinthia H. Higuchi, et al.
Published: (2014-12-01)

Gene signatures of responders vs. non-responders to inhaled endotoxin challenge
by: David Peden, et al.
Published: (2020-08-01)

Impulsivity and risk taking in bipolar disorder and schizophrenia
by: Reddy, L, et al.
Published: (2014)

Fronto-temporal connections in schizophrenia and bipolar disorder
by: Paez Rodriguez, P
Published: (2011)

Impulsivity and risk taking in bipolar disorder and schizophrenia.
by: Reddy, L, et al.
Published: (2014)

Brain Hemispheric Asymmetry in Schizophrenia and Bipolar Disorder
by: Diogo Pinto, et al.
Published: (2023-05-01)

The response to unfolded proteins in schizophrenia and bipolar disorder
by: C. Cachán, et al.
Published: (2023-03-01)